Humira (adalimumab) is a biologic medication used to treat a wide range of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, and juvenile plaque psoriasis. As a biologic, Humira is composed of complex proteins that are difficult to replicate, making it a challenge for generic drug manufacturers to produce a generic version of the biologic. Biosimilars are a type of generic drug designed to replicate the same therapeutic effect as a biologic, but may be composed of different non-active ingredients. In 2023, biosimilars of Humira are expected to be available on the market.
How Biosimilars Work
Biosimilars are an alternative to traditional generics, and work by replicating the same therapeutic effect as the original biologic. While biosimilars are similar to the original biologic, they are not identical. Biosimilars are made from living organisms and have to be grown, so they cannot be exact replicas of the original drug. Biosimilars are manufactured according to strict regulations, including pre-clinical and clinical trials, and must meet the same standards as the original biologic to be approved by the FDA. However, biosimilars may have different non-active ingredients, and may bind differently to different proteins, so it is important to discuss any potential side effects with a doctor before taking a biosimilar.
Humira Biosimilars in 2023
In 2023, Humira biosimilars are expected to become available on the market. The first biosimilar of Humira, Amgevita (adalimumab-abda), was approved by the FDA in 2017, but the patent for Humira does not expire until 2023. Once the patent expires, biosimilars of Humira will become available and will provide a more cost-effective option for patients. Additionally, biosimilars of Humira will provide more competition in the marketplace, which could drive prices down.
Potential Side Effects of Humira Biosimilars
Humira biosimilars may have different non-active ingredients, and may bind differently to different proteins, so it is important to discuss any potential side effects with a doctor before taking a biosimilar. The most common side effects of Humira include nausea, headache, abdominal pain, and injection site reactions. Additionally, Humira may increase the risk of certain infections, including serious infections such as tuberculosis, so it is important to discuss any potential risks with a doctor before taking a biosimilar.
Conclusion
Humira biosimilars are expected to become available on the market in 2023, providing a more cost-effective option for patients. While biosimilars are designed to replicate the same therapeutic effect as the original biologic, they may have different non-active ingredients, so it is important to discuss any potential side effects with a doctor before taking a biosimilar. Additionally, it is important to discuss any potential risks with a doctor before taking a biosimilar, as Humira may increase the risk of certain infections.